These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

443 related articles for article (PubMed ID: 33298620)

  • 1. A20 regulates the therapeutic effect of anti-PD-1 immunotherapy in melanoma.
    Guo W; Ma J; Guo S; Wang H; Wang S; Shi Q; Liu L; Zhao T; Yang F; Chen S; Chen J; Zhao J; Yu C; Yi X; Yang Y; Ma J; Ni Q; Zhu G; Gao T; Li C
    J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33298620
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In situ immunogenic clearance induced by a combination of photodynamic therapy and rho-kinase inhibition sensitizes immune checkpoint blockade response to elicit systemic antitumor immunity against intraocular melanoma and its metastasis.
    Kim S; Kim SA; Nam GH; Hong Y; Kim GB; Choi Y; Lee S; Cho Y; Kwon M; Jeong C; Kim S; Kim IS
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33479026
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nuclear imaging-guided PD-L1 blockade therapy increases effectiveness of cancer immunotherapy.
    Gao H; Wu Y; Shi J; Zhang X; Liu T; Hu B; Jia B; Wan Y; Liu Z; Wang F
    J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33203663
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Casp8 acts through A20 to inhibit PD-L1 expression: The mechanism and its implication in immunotherapy.
    Zou J; Xia H; Zhang C; Xu H; Tang Q; Zhu G; Li J; Bi F
    Cancer Sci; 2021 Jul; 112(7):2664-2678. PubMed ID: 33934451
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Automated Quantitative CD8+ Tumor-Infiltrating Lymphocytes and Tumor Mutation Burden as Independent Biomarkers in Melanoma Patients Receiving Front-Line Anti-PD-1 Immunotherapy.
    Fortman D; Karunamurthy A; Hartman D; Wang H; Seigh L; Abukhiran I; Najjar YG; Pantanowitz L; Zarour HM; Kirkwood JM; Davar D
    Oncologist; 2024 Jul; 29(7):619-628. PubMed ID: 38655867
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SOX2 promotes resistance of melanoma with PD-L1 high expression to T-cell-mediated cytotoxicity that can be reversed by SAHA.
    Wu R; Wang C; Li Z; Xiao J; Li C; Wang X; Kong P; Cao J; Huang F; Li Z; Huang Y; Chen Y; Li X; Yang D; Zhang H; Mai J; Feng G; Deng R; Zhu X
    J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33158915
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interruption of the intratumor CD8
    Geels SN; Moshensky A; Sousa RS; Murat C; Bustos MA; Walker BL; Singh R; Harbour SN; Gutierrez G; Hwang M; Mempel TR; Weaver CT; Nie Q; Hoon DSB; Ganesan AK; Othy S; Marangoni F
    Cancer Cell; 2024 Jun; 42(6):1051-1066.e7. PubMed ID: 38861924
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glucocorticoid activation by HSD11B1 limits T cell-driven interferon signaling and response to PD-1 blockade in melanoma.
    Martins Nascentes Melo L; Herrera-Rios D; Hinze D; Löffek S; Oezel I; Turiello R; Klein J; Leonardelli S; Westedt IV; Al-Matary Y; Egea-Rodriguez S; Brenzel A; Bau M; Sucker A; Hadaschik E; Wirsdörfer F; Hanenberg H; Uhlenbrock N; Rauh D; Poźniak J; Rambow F; Marine JC; Effern M; Glodde N; Schadendorf D; Jablonska J; Hölzel M; Helfrich I
    J Immunother Cancer; 2023 Apr; 11(4):. PubMed ID: 37028818
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The ERK inhibitor LY3214996 augments anti-PD-1 immunotherapy in preclinical mouse models of BRAFV600E melanoma brain metastasis.
    de Sauvage MA; Torrini C; Nieblas-Bedolla E; Summers EJ; Sullivan E; Zhang BS; Batchelor E; Marion B; Yamazawa E; Markson SC; Wakimoto H; Nayyar N; Brastianos PK
    Neuro Oncol; 2024 May; 26(5):889-901. PubMed ID: 38134951
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nanomicelle protects the immune activation effects of Paclitaxel and sensitizes tumors to anti-PD-1 Immunotherapy.
    Yang Q; Shi G; Chen X; Lin Y; Cheng L; Jiang Q; Yan X; Jiang M; Li Y; Zhang H; Wang H; Wang Y; Wang Q; Zhang Y; Liu Y; Su X; Dai L; Tang M; Li J; Zhang L; Qian Z; Yu D; Deng H
    Theranostics; 2020; 10(18):8382-8399. PubMed ID: 32724476
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergy between
    Zhu YC; Elsheikha HM; Wang JH; Fang S; He JJ; Zhu XQ; Chen J
    J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34725213
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
    Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
    J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The PD-1/PD-L1-Checkpoint Restrains T cell Immunity in Tumor-Draining Lymph Nodes.
    Dammeijer F; van Gulijk M; Mulder EE; Lukkes M; Klaase L; van den Bosch T; van Nimwegen M; Lau SP; Latupeirissa K; Schetters S; van Kooyk Y; Boon L; Moyaart A; Mueller YM; Katsikis PD; Eggermont AM; Vroman H; Stadhouders R; Hendriks RW; Thüsen JV; Grünhagen DJ; Verhoef C; van Hall T; Aerts JG
    Cancer Cell; 2020 Nov; 38(5):685-700.e8. PubMed ID: 33007259
    [TBL] [Abstract][Full Text] [Related]  

  • 14. eEF2K promotes PD-L1 stabilization through inactivating GSK3β in melanoma.
    Chen X; Wang K; Jiang S; Sun H; Che X; Zhang M; He J; Wen Y; Liao M; Li X; Zhou X; Song J; Ren X; Yi W; Yang J; Chen X; Yin M; Cheng Y
    J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35347072
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antimetabolite pemetrexed primes a favorable tumor microenvironment for immune checkpoint blockade therapy.
    Lu CS; Lin CW; Chang YH; Chen HY; Chung WC; Lai WY; Ho CC; Wang TH; Chen CY; Yeh CL; Wu S; Wang SP; Yang PC
    J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33243934
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemoradiation triggers antitumor Th1 and tissue resident memory-polarized immune responses to improve immune checkpoint inhibitors therapy.
    Lauret Marie Joseph E; Kirilovsky A; Lecoester B; El Sissy C; Boullerot L; Rangan L; Marguier A; Tochet F; Dosset M; Boustani J; Ravel P; Boidot R; Spehner L; Haicheur-Adjouri N; Marliot F; Pallandre JR; Bonnefoy F; Scripcariu V; Van den Eynde M; Cornillot E; Mirjolet C; Pages F; Adotevi O
    J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34230108
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting STAT3 Abrogates Tim-3 Upregulation of Adaptive Resistance to PD-1 Blockade on Regulatory T Cells of Melanoma.
    Huang L; Xu Y; Fang J; Liu W; Chen J; Liu Z; Xu Q
    Front Immunol; 2021; 12():654749. PubMed ID: 33936081
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An advanced comprehensive muti-cell-type-specific model for predicting anti-PD-1 therapeutic effect in melanoma.
    Sun W; Zhu Y; Zou Z; Wang L; Zhong J; Shen K; Lin X; Gao Z; Liu W; Li Y; Xu Y; Ren M; Hu T; Wei C; Gu J; Chen Y
    Theranostics; 2024; 14(5):2127-2150. PubMed ID: 38505619
    [No Abstract]   [Full Text] [Related]  

  • 20. Single-cell transcriptome analysis reveals TOX as a promoting factor for T cell exhaustion and a predictor for anti-PD-1 responses in human cancer.
    Kim K; Park S; Park SY; Kim G; Park SM; Cho JW; Kim DH; Park YM; Koh YW; Kim HR; Ha SJ; Lee I
    Genome Med; 2020 Feb; 12(1):22. PubMed ID: 32111241
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.